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Aims To examine the risk of death associated with antiarrhythmic drug (AAD) therapy in a nationwide unselected cohort
of patients with atrial fibrillation (AF).
Methods
and results
All patients admitted with AF in Denmark from 1995 to 2004 and their subsequent use of AADs were identified by
individual-level linkage of nationwide registries. Multivariable Cox proportional-hazard models with time-dependent
covariates were used to analyse the risk of death associated with AAD therapy. A total of 141 500 patients were
included in the study; of these 3356 (2.4%) patients received treatment with flecainide, 3745 (2.6%) propafenone,
23 346 (16.5%) sotalol, and 10 376 (7.3%) amiodarone. Annualized mortality rates were 2.54, 4.25, 5.29, and 7.42
per year per 100 person years for flecainide, propafenone, sotalol, and amiodarone, respectively. Multivariable
Cox proportional-hazard models did not show increased risk of death associated with any of the AADs. Hazard
ratio (95% confidence interval) for flecainide 0.38 (0.32–0.44), propafenone 0.65 (0.58–0.71), sotalol 0.65 (0.63–
0.67), and amiodarone 0.94 (0.89–1.00).
Conclusion In an unselected cohort of patients with AF, antiarrhythmic treatment with flecainide, propafenone, sotalol, or amio-
darone was not associated with increased risk of death. From a safety perspective, this indicates appropriate selection
of patients for AAD therapy.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords Antiarrhythmic drug therapy † Atrial fibrillation
Introduction
Antiarrhythmic drug (AAD) treatment has been associated with
increased risk of death in several studies of patients with under-
lying structural or ischaemic heart disease.1,2 Consequently, a vig-
ilant focus has been maintained of appropriate selection of
patients to receive this potentially harmful therapy, which is
often used to treat relatively benign rhythm disturbances such
as atrial fibrillation (AF) and other supraventricular tachyarrhyth-
mias. This discussion has become even more relevant after publi-
cations of large randomized trials failing to show any mortality
benefits of rhythm control over rate control in the treatment
of AF.3– 5
Over the last decade, there has been a shift towards increased
use of second and third generation beta-blockers in lieu of pri-
marily sotalol but also of class IC drugs such as flecainide and
propafenone.6 This change may partly reflect a heightened aware-
ness of the proarrhythmic risk posed by these drugs as demon-
strated in various trials and reviews.1,7 – 9 Whether a significant
risk is associated with AAD therapy in a large nationwide unse-
lected population is as yet unresolved. In the present study, we
examined the risk of death associated with treatment with flecai-
nide, propafenone, amiodarone, or sotalol among 141 500
patients hospitalized with AF in the period 1995–2004 in
Denmark.
* Corresponding author. Tel: þ45 20 27 01 83, Fax: þ45 70 20 12 81, Email: ssa@heart.dk
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Methods
Population
The cohort of patients selected for this study was identified using the
Danish National Patient Registry, a nationwide registry of all hospital-
izations in Denmark since 1978. Patients hospitalized with first-time
AF [International Classification of Diseases, 10th revision (ICD-10),
code I48] as a primary or secondary diagnosis between 1995 and
2004 were identified. All patients alive at discharge were included in
the analyses.
Medical treatment
Information on the use of pharmacotherapy was obtained from the
Registry of Medicinal Product Statistics (national prescription registry),
which includes all prescriptions dispensed from Danish pharmacies
since 1995. The national prescription registry also keeps information
on date of dispensing, strength, quantity dispensed, and the affiliation
of the doctor issuing the prescription. Each prescribed drug is coded
according to an international classification of pharmaceuticals, the ana-
tomical therapeutical chemical (ATC) classification. The registry has
been found to be accurate and has been described in more detail
previously.10
All prescriptions of flecainide, propafenone, sotalol, and amiodarone
(ATC codes C01BC04, C01BC03, C07AA07, and C01BD01) claimed
in the 10-year period from 1995 to 2004 by the study population fol-
lowing the index admission were identified. From all claimed prescrip-
tions, the treatment duration and the mean dosage were calculated for
every patient. In order to obtain information concerning concomitant
medical treatment, prescriptions claimed, within 180 days before dis-
charge from index admission, of loop diuretics, glucose lowering medi-
cation (insulin and oral), statins, digoxin, calcium antagonists,
beta-blockers, warfarin, angiotensin-converting enzyme inhibitors,
and potassium sparing diuretics were also identified (ATC codes
C03C, A10B, C10AA, C01A, C08, C07AB, B01AA03, C09D, C031).
Vital status
Vital status as of the end of December 2004 was obtained from the
Civil Registration System.
Comorbidity
We identified diagnoses of comorbidity at the index admission and
further enhanced the comorbidity index by identifying diagnoses at
admissions up to 1 year prior to the index admission, as done by Ras-
mussen et al.11 The following comorbidity diagnoses were identified
and included in the analyses: ischaemic heart disease (ICD codes
I20–I25), chronic heart failure (CHF) (I50), arrhythmias other than
AF (I46, I47, I49), cerebrovascular disease (I60–I69), peripheral vascu-
lar disease (I70, I74), chronic obstructive pulmonary disease (COPD)
(J42–J44), diabetes mellitus (E10–E14), and malignancy (C00–C97)
(Table 1).
Exposure groups and dosages
Patients were categorized into exposure groups depending on the
AAD used at their first prescription claim following the index admis-
sion [flecainide, propafenone, sotalol, or amiodarone (Table 1)]. The
average daily dosage for each patient was calculated as the mean
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Table 1 Baseline characteristics of the study population
Characteristic Total Any use of
flecainide
Any use of
propafenone
Any use of sotalol Any use of
amiodarone
Number 141 500 3356 3745 23 346 10 376
Women (%) 47.2 38.7 38.7 41.1 33.7
Age, mean+ SD (years) 72.6+12.9 60.9+11.7 63.9+11.6 66.4+11.9 67.2+11.1
Women, age 75.9+11.9 64.9+11.4 67.3+11.4 70.2+11.1 70.8+10.0
Men, age 69.7+13.1 58.4+11.3 61.8+11.3 63.7+11.8 65.4+11.2
Comorbidity
Previous MI 8466 (5.9) 41 (1.2) 83 (2.2) 1173 (5.0) 1021 (9.8)
Ischaemic heart disease 23 000 (16.3) 212 (6.3) 404 (10.8) 3508 (15.0) 2525 (24.3)
Congestive heart failure 25 195 (17.8) 153 (4.6) 285 (7.6) 2224 (9.5) 2234 (21.5)
Other arrhythmia 7818 (5.5) 363 (10.8) 319 (8.5) 1740 (7.5) 1243 (11.9)
Cerebrovascular disease 13 297 (9.4) 90 (2.7) 122 (3.3) 1049 (4.5) 456 (4.4)
Peripheral vascular disease 2657 (1.9) 11 (0.3) 29 (0.8) 231 (0.9) 171 (1.7)
COPD 10 856 (7.7) 114(3.4) 228(6.1) 426 (1.8) 845 (8.1)
Diabetes 10 437 (7.4) 66(1.9) 135(3.6) 1002 (4.3) 697 (6.7)
Malignant condition 3437 (2.4) 22(0.7) 30(0.8) 267 (1.1) 155 (1.5)
Concomitant medical treatment
Beta-1-selective blockers 25 434 (17.9) 501 (14.9) 526 (14.1) 4269 (18.3) 2504 (24.1)
Calcium antagonists 33 760 (23.9) 759 (22.6) 946 (25.3) 5515 (23.6) 2682 (25.9)
Digoxin 53 270 (37.7) 1017 (30.3) 1396 (37.3) 7744 (33.2) 3759 (36.2)
Warfarin 24 879 (17.6) 747 (22.3) 862 (23.0) 5045 (21.6) 2503 (24.1)
Loop diuretics 47 194 (33.4) 385 (11.5) 732 (19.6) 5065 (21.7) 3813 (36.8)
Statins 9128 (6.5) 118 (3.5) 186 (4.9) 1497 (6.4) 1175 (11.3)
Glucose lowering medication 8656 (6.1) 70 (2.1) 135 (3.6) 1002 (4.3) 555 (5.4)
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dosage from all prescriptions claimed. As amiodarone was the only
AAD with a long plasma half-life and thus potential for a carryover
of risk in relation to treatment switch, it was ascertained how many
patients who were actually exposed to this risk. The amount was
small (n ¼ 189) and no deaths occurred within 3 months of amiodar-
one cessation. It was therefore not included as a covariate in the
analyses.
Endpoint
The predefined endpoint of interest was all-cause mortality.
Statistical analyses
To strengthen the findings, three different statistical analyses were
employed to estimate the potential risks associated with AAD
therapy. Initially, Cox regression models with AAD treatment as time-
dependent covariate were used. The time-dependent exposure vari-
able ensured that patients were only considered at risk when receiving
the medication (exposed). All models were adjusted for age, gender,
calendar year, comorbidity, and concomitant medical treatment (as
listed in Table 1). The reference group for the models were all patients
not in AAD treatment, and for sensitivity analyses, AAD-treated
patients out of treatment as reference were also performed. The
model assumptions, linearity of continuous variables, and lack of inter-
actions were tested and found valid. Additionally, tests of differences
between the linear hypotheses of the Cox models were conducted
and were shown to be significant. Patients were censored in the
event of death and at the end of the study period (31 December
2004).
Secondly, a propensity score analysis was performed to enhance the
accuracy of the Cox models by dividing the population into closely
matched groups defined by the propensity to receive a specific AAD
within 90 days conditional on the baseline covariates. Multivariate
Cox models were then used to assess hazard ratios between the
groups. The C-statistic for this model was 0.80, indicating good dis-
crimination between treatment groups.
Thirdly, to minimize the effect of unmeasured confounders, case-
crossover analyses with the use of conditional logistical regression
models12 were employed. The case-crossover analysis is based on
the case-base paradigm, but instead of using matched controls the
case serves as its own control in other periods than the case period.
Only patients experiencing an event of interest are included in the
case-crossover analysis. Among these patients, the number having
medication available in the case period (which is the period immedi-
ately before the event of interest) is compared with the number
having medication available in the control period (which is a period
further back in time than the case period but of the same length as
the case period). The case period was defined as treatment during
0–30 days prior to death and as control: two periods of 60–90 and
90–120 days prior to death were used.
All statistical calculations were performed using the SAS statistical
software package, version 9.1 (SAS Institute Inc., Cary, NC, USA).
Ethics
The Danish Data Protection Agency approved this study (No.
2003-54-1269). Retrospective registry-based studies do not require
ethical approval in Denmark.
Results
Between 1995 and 2005, 141 500 patients were discharged alive
after a first-time hospitalization for AF. Baseline characteristics of
the study population are shown in Table 1. Following discharge, a
total of 40 823 (28.9%) patients claimed a prescription for an
AAD. Flecainide (n ¼ 3356; 2.4%), propafenone (n ¼ 3745;
2.6%), sotalol (n ¼ 23 346; 16.5%), or amiodarone (n ¼ 10 376;
7:3%). A higher prevalence of male gender and younger age was
present in the treatment groups compared with patients not
receiving AAD therapy. Patients receiving amiodarone had the
highest prevalence of comorbidity and concomitant medication
compared with the other exposure groups. Conversely, patients
who received class 1C AADs had a lower prevalence of comorbid-
ity and concomitant pharmacotherapy. Of the entire cohort, 5.0%
received treatment with class 1C AADs. The mean follow-up of
the total study cohort was 3.2 years after discharge (SD 2.7 years).
Mean dosages of the AADs were for flecainide 205.6 mg (SD
+56.1 mg), propafenone 411.4 mg (+117.0 mg), sotalol
122.9 mg (+49.7 mg), amiodarone 287.4 mg (+87.9 mg).
The duration of treatment for patients receiving class 1C AADs
was slightly longer than those treated with sotalol or amiodarone
(Table 2).
Mortality
Between 1995 and 2005, there were 62 173 (43.9%) deaths
registered (Table 2). There were fewer deaths (n ¼ 11 080;
27.1%) in the treatment groups compared with the entire
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Table 2 Mean daily dosages, average duration of follow-up, and time in treatment
Number
of
patients
Mean
dosage (mg)
Average
duration of
follow-up
(year)
Average
duration of
treatment
(year)
All deaths
during
follow-up
(%)
Deaths
during
treatment
(%)
Deaths within
30 days of
initiating
treatment (%)
Annualized
mortality
rates (per
year per 100
person years)
Flecainide 3356 205.6+56.1 5.8 2.4 492 (14.7) 160 (4.8) 14 (0.4) 2.54
Propafenone 3745 411.4+117.0 5.5 2.3 877 (23.4) 342 (9.1) 20 (0.5) 4.25
Sotalol 23 346 122.9+49.7 5.2 1.7 6464 (27.7) 3145 (13.5) 192 (0.8) 5.29
Amiodarone 10 376 287.4+87.9 4.2 1.6 3247 (31.3) 1779 (17.1) 212 (2.0) 7.42
Total cohort 141 500 62 173 (43.9)
All deaths during follow-up. Deaths during treatment and within 30 days of initiating treatment. Annualized mortality rates (deaths per year per 100 person years).
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population. Very few deaths occurred within 30 days of treat-
ment initiation and deaths in the treatment groups occurred
most frequently after the patients had stopped taking the medi-
cation and were thus unexposed to the AAD. Annualized mor-
tality rates were 2.54, 4.25, 5.29, and 7.42 per year per 100
person years for flecainide, propafenone, sotalol, and amiodar-
one, respectively (Table 2). Incidence rates for deaths demon-
strated significantly lower rates in all the treatment groups
over time compared with the population receiving no AAD
therapy (Figure 1). In the multivariable Cox proportional-hazard
analysis, the risk of death was significantly lower in all treatment
groups except for the amiodarone group, where the risk was
not different from those not receiving AADs (Table 3). The
propensity-score matched analysis and the case-crossover
models confirmed these findings (Table 3).
Discussion
This study examined the cardiovascular risk associated with AAD
treatment in an unselected population of patients discharged
after first hospitalization for AF. The main findings were that
AAD therapy was not associated with increased risk of death in
patients with AF. Deaths occurring in the treatment groups were
fewer than observed in the population not receiving AADs. Also,
deaths occurring in the treatment groups, particularly for the fle-
cainide and propafenone groups and partly for the sotalol recipi-
ents, were predominantly observed after AAD therapy had been
discontinued. Additionally, very few deaths were observed within
30 days of treatment initiation where fatalities in patients suscep-
tible to the proarrhythmic effects of AADs might be highest.
Somewhat unexpectedly, there were relatively large percentages
Figure 1 Incidence rates for deaths in all treatment groups and in the population receiving no antiarrhythmics. Time starts from the day of
prescription claim. For patients receiving no antiarrhythmic drugs, time starts 60 days following discharge.
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Table 3 Risk of death assessed by the three modalities: Cox analyses with the study drug as time-dependent variable,
propensity scorematching by propensity to receive study drug, and case-crossover analyses with 0–30 days prior to death
being case period and 60–90 and 90–120 days prior to death being control periods
Exposure
group
Cox analyses with time-dependent variables
[Hazard ratio (95% CI)]
Propensity analyses [Hazard
ratio (95% CI)]
Case-crossover analyses [Hazard
ratio (95% CI)]
Flecainide 0.38 (0.32–0.44) 0.55 (0.46–0.65) 0.32 (0.18–0.59)
Propafenone 0.65 (0.58–0.71) 0.61 (0.41–0.91) 0.62 (0.40–0.96)
Sotalol 0.65 (0.63–0.67) 0.62 (0.52–0.73) 0.36 (0.29–0.42)
Amiodarone 0.94 (0.89–1.00) 0.94 (0.74–1.17) 0.81 (0.70–0.94)
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of patients with IHD or CHF receiving treatment with class 1C
AADs (Table 1), although this did not seem to affect the outcome.
Our study thereby indicates no increased mortality among
patients selected to receive this treatment as recommended by
international guidelines.13 These findings remained consistent in
several different statistical models.
International guidelines13 recommend sotalol, flecainide, and
propafenone as first-line drugs when attempting to maintain
sinus rhythm in AF patients without underlying structural heart
disease. However, as previously documented, in the Danish popu-
lation prescription of these drugs has declined rapidly over the last
years in lieu of conventional beta-blockers.6 This shift may partly
derive from the results of studies such as CAST1 and SWORD2
where treatment with 1C AADs and sotalol in patients with struc-
tural heart disease was clearly associated with increased mortality.
However, for patients with AF without cardiac comorbidity, an
increased mortality risk associated with the use of AADs has
never been shown. Nichol et al.14 evaluated the effectiveness of
AAD therapy to maintain sinus rhythm in patients with AF in a
large meta-analysis, but while containing many relevant randomized
trials, it lacked the statistical power to evaluate the possible effect
on mortality when using AADs in the setting of AF.
In a substudy of the Atrial Fibrillation Follow-up Investigation of
Rhythm Management (AFFIRM), which examined the cause-specific
modes of death, no differences were found between the rate- and
rhythm-control groups concerning fatal cardiac outcomes.15
Notably, there were no differences in the numbers of
arrhythmia-related deaths between the groups. In another AFFIRM
substudy evaluating the risk of proarrhythmic events in the rhythm
control group, a low incidence of events and a prognostic indicator
being left ventricular ejection fraction ,40% was demonstrated.16
Results from our study corroborate the AFFIRM findings in a large
unselected population as we found no increased risk of death associ-
ated with AAD treatment. It should be noted however that there are
differences in the baseline characteristics in the rhythm arm of the
AFFIRM population compared with the segment of our population
receiving treatment with 1C AADs and sotalol. The AFFIRM patients
were older and had a much higher prevalence of coronary heart
disease as well as history of CHF. It is also of interest to note that
the few instances of arrhythmic events in the rhythm-control group
indicate that an appropriate AAD therapy was selected by physicians.
We believe this also applied to our population considering that the
lower mortality risk in the treatment groups persisted even when
compared with similar patients in the no-AAD population as demon-
strated in the propensity analyses. This could be attributed to a
hitherto unknown mortality benefit associated with the flecainide,
propafenone, or sotalol use, but more likely it reflects an underlying
selection bias whereby the treating physician identifies the patients in
whom AAD treatment is appropriate by factors not apparent from
the registry data. This could also represent a reluctance to prescribe
AAD treatment even in patients where the benefits are likely to out-
weigh the risks. This bias also includes the fact that any deterioration
of the patient is likely to cause discontinuation of antiarrhythmic
therapy. But the important finding, as previously mentioned, is the
lack of increased mortality risk in patients receiving AAD treatment.
In light of the AFFIRM results where rhythm- and rate-control strat-
egies were considered equal in terms of mortality, a shift in clinical
practice towards more rate control is to be expected in elderly
asymptomatic AF patients, especially given the trend towards a
higher mortality in the rhythm-control arm driven by the non-
cardiovascular deaths. In subsets of AF patients with concomitant
severe CHF, a recent study has also failed to demonstrate superiority
of rhythm control, and attempting rhythm control in these patients
with newer and perhaps promising AADs such as dronedarone has
been shown to actually increase mortality.5,17 However, for
younger symptomatic AF patients without structural heart disease,
rate control may be associated with significantly poorer quality of
life, making rhythm control, and thereby AAD-therapy the most
viable treatment option. Our study indicates that for these patients
such a strategy imposes no greater risk.
Strengths and limitations
The main strengths of this study are the large study cohort in an
unselected patient population, the completeness of the data and
the inclusion of nationwide data including the prescription practice
of all hospitals in Denmark. Thereby, the study avoids selection
bias such as only including certain age groups, groups of certain
socioeconomic status, certain hospitals, or participants in particu-
lar health insurance plans. To avoid immortal time bias where the
drug-treated patients are immune to events until first prescription
claim, Cox proportional-hazards analyses with a time-dependent
definition for the drug exposure were used.
The main limitation is the retrospective non-randomized nature
of the study. Detailed information about important factors such as
biochemical parameters, family history, drug allergies, smoking, and
physician assessed level of compliance to a particular treatment
cannot be obtained from these administrative registries, and the
adjustment for comorbidity may be insufficient. Another main
bias is physicians’ awareness of the hazard of AAD treatment,
which is evident from the demographic data where many high-risk
patients were never given AAD treatment. Furthermore, phys-
icians are likely to discontinue treatment if the patient’s condition
worsens which presumably is the most likely explanation why most
fatalities occur after discontinuation of therapy.
Conclusions
In a large unselected population-based cohort of patients discharged
with the first-time AF and subsequently treated with flecainide, pro-
pafenone, sotalol, or amiodarone, we found no increased risk of
death. This indicates adequate patient selection by the treating phys-
icians from a safety perspective. Our findings corroborate the rec-
ommendations outlined in current international guidelines for the
treatment of AF. Furthermore, this study underscores the impor-
tance of appropriate risk stratification and individual patient evalu-
ation before initiating AAD therapy in AF patients.
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